News Releases

Patent expected to provide intellectual property protection for Keveyis through 2039 Reinforces Xeris’ commitment to the primary periodic paralysis community and the patients who rely on Keveyis CHICAGO --(BUSINESS WIRE)--Jun. 11, 2026-- Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of

Eliminates approximately $23 million of debt, resulting in approximately $2 million in annual interest savings Principal to be paid in cash, remainder in common stock CHICAGO --(BUSINESS WIRE)--Jun. 11, 2026-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company

Total product revenue increased 43% year-over-year to over $82 million Recorlev net revenue increased 95% year-over-year to $50 million Tightens full-year 2026 total revenue guidance to $380 million to $390 million Hosts conference call and webcast today at 8:30 a.m.

Conference Call to be Held at 8:30 a.m. ET CHICAGO --(BUSINESS WIRE)--Apr. 23, 2026-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today

CHICAGO --(BUSINESS WIRE)--Apr. 3, 2026-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on April 1, 2026, the

Achieved record quarterly and full-year total revenue of $86 million and $292 million, respectively Provides full year 2026 total revenue guidance range of $375 million to $390 million Hosts conference call and webcast today at 8:30 a.m. ET CHICAGO --(BUSINESS WIRE)--Mar.

Four Orange Book Listed Patents through March 2040 Orphan Drug Exclusivity through December 2028 CHICAGO --(BUSINESS WIRE)--Feb. 26, 2026-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing

Conference Call to be Held at 8:30 a.m. ET CHICAGO --(BUSINESS WIRE)--Feb. 17, 2026-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today

Anticipates full year 2025 total revenue of $292 million , exceeding the guidance range of $285-$290 million and reflecting growth of 44% compared to the prior year Expects fourth quarter and full year 2025 Recorlev ® net revenue of $45 million and $139 million , respectively Full-year 2025

CHICAGO --(BUSINESS WIRE)--Jan. 2, 2026-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on January 2, 2026 , the